@minoryx.com
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Minoryx is a pioneering brand that focuses on the discovery and development of innovative treatments for severe orphan diseases of the central nervous system (CNS) with a high unmet medical need. Committed to bringing new hope to people suffering from these life-threatening conditions, Minoryx offers solutions for patients with orphan CNS diseases. Their leading program revolves around the development of a novel and selective PPAR gamma agonist called leriglitazone.
This groundbreaking treatment is currently in clinical development for multiple orphan CNS disorders, with its primary indication being X-linked Adrenoleukodystrophy (X-ALD). Preclinical studies have showcased the robust proof-of-concept of leriglitazone in animal models of the disease, and phase 1 clinical trials have been successfully completed. In addition to its potential in X-ALD, leriglitazone also demonstrates promise in other CNS diseases.
For instance, a proof-of-concept study in Friedreich's Ataxia (FRDA) has shown clinical benefit, leading to the preparation of a phase 3 study in this population. With their wholly-owned lead asset, leriglitazone, Minoryx is determined to deliver innovative treatments and make a significant impact on the lives of patients suffering from orphan CNS disorders
Company Type
Privately Held
Company Size
11-50
Year Founded
2011
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories